Results 181 to 190 of about 36,987 (240)

ADGRE2: A Promising Immunotherapeutic Target in Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) are heterogeneous myeloid malignancies with limited therapeutic options and often poor long‐term prognosis due to persistence of therapy‐resistant leukemic stem cells (LSC).
Jennifer Neiss   +9 more
wiley   +1 more source

SLE Complicated With AIHA and Parvovirus B19 Infection Secondary to PRCA: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 11, November 2026.
We report the diagnosis and treatment process of a female with SLE and AIHA infected with parvovirus B19 and secondary PRCA. Interestingly, there was no significant increase in hemoglobin after IVIG treatment for more than 50 days; however, the addition of foscarnet showed good efficacy.
Mingquan Xing   +4 more
wiley   +1 more source

Zanubrutinib Combined With Venetoclax for the Treatment of Central Nervous System‐Involved Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Rare Case Report

open access: yesCancer Reports, Volume 9, Issue 11, November 2026.
ABSTRACT Background Clinically significant CNS involvement by CLL/SLL is uncommon, diagnostically challenging, and has no established standard treatment. Case A 61‐year‐old man with previously untreated CLL/SLL was admitted in April 2023 to Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, with rapidly
Wei Xie   +4 more
wiley   +1 more source

Scalable Arrayed T‐cell CRISPR Screening in Autologous Tumor Co‐cultures to Prioritize Combination Partners for T‐cell Engagers

open access: yesCurrent Protocols, Volume 6, Issue 11, November 2026.
Abstract T‐cell‐engaging therapies (TCE) have shown clinical promise in hematologic malignancies, but the T‐cell‐intrinsic determinants of TCE‐mediated cytotoxicity remain incompletely defined. This is in part because functional studies in patient‐derived primary samples have been technically challenging.
Keenan Ernste   +9 more
wiley   +1 more source

Evaluating the Sensitivity of Airborne eDNA for Detecting Myotis Bats: Recommendations for Sampling Design

open access: yesEnvironmental DNA, Volume 8, Issue 6, November‐December 2026.
We conducted field trials under high bat density, low bat density, and winter conditions to evaluate the sensitivity of airborne eDNA for detecting Myotis bats. Our findings highlight the potential and current limitations of these methods and provide a foundation for refining sampling strategies.
Samantha E. Gidora   +10 more
wiley   +1 more source

Impact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC

open access: yesHemaSphere, Volume 10, Issue 11, November 2026.
Abstract The impact of venetoclax‐based therapies on autoimmune cytopenias (AIC) in patients with chronic lymphocytic leukemia (CLL) is largely unknown. This study aimed to evaluate preexisting and treatment‐emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax‐based ...
Candida Vitale   +106 more
wiley   +1 more source

Decision‐Making on First‐Line Treatment Alternatives in Chronic Lymphocytic Leukemia: A Multi‐Criteria Decision Analysis to Elicit Stakeholders' Preferences in Italy

open access: yesHematological Oncology, Volume 44, Issue 6, November 2026.
ABSTRACT Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries. The introduction of targeted therapies has expanded first‐line treatment options, which differ across multiple relevant dimensions, making therapeutic decisions increasingly challenging.
Paolo Sportoletti   +10 more
wiley   +1 more source

Targeted Protein Degradation: From Molecular Mechanisms to Emerging Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 11, November 2026.
Graphical overview of targeted protein degradation: mechanisms, molecular determinants, delivery strategies, and therapeutic development. This graphical abstract summarizes the major degradation pathways involved in targeted protein degradation, including the ubiquitin–proteasome system, endocytosis–lysosome pathway, and autophagy‐dependent degradation.
Huaijuan Guo   +8 more
wiley   +1 more source

Trends and socio‐economic disparities in chronic lymphocytic leukaemia 2014–2022: An England‐wide cohort study from the UNCOVER group

open access: yesBritish Journal of Haematology, Volume 209, Issue 5, Page 2056-2065, November 2026.
Summary To re‐evaluate chronic lymphocytic leukaemia (CLL) epidemiology in the era of modern therapy, data were extracted from the English National Cancer Registration Dataset (NCRD). A total of 34 427 consecutive diagnoses of CLL were recorded (2014–2022), the largest European dataset on record.
Temitope Erinfolami   +18 more
wiley   +1 more source

Warm autoimmune haemolytic anaemia in Taiwan: A population‐based study of epidemiology, treatment patterns, survival and healthcare utilisation (2017–2022)

open access: yesBritish Journal of Haematology, Volume 209, Issue 5, Page 2273-2283, November 2026.
Summary To describe the epidemiology, treatment patterns, overall survival (OS) and healthcare resource use among patients with warm autoimmune haemolytic anaemia (wAIHA) in Taiwan, adult patients with ≥1 diagnosis code for autoimmune haemolytic anaemia (AIHA) with record of wAIHA‐related treatments between 2017 and 2022 were retrospectively identified
Hsiao‐Wen Kao   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy